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Rosacea is a chronic inflammatory skin disease that primarily affects the central area of the face; it is 
characterized by erythema, papules, pustules, nodules, and telangiectasia. This condition arises between 
30–60 years of age, and it usually occurs in fair‑skinned people. Rosacea is characteristic of sensitive 
skin, as it is a disease marked with punctuated phases of exacerbated signs and symptoms that alternate 
with periods of remission. Humans have long incorporated cosmetics in their daily habits; given the 
scientific and technological developments that emerged in cosmeceuticals or dermocosmetics, the 
current cosmetic options are now used for much more than adornment or cleansing. The purpose of 
cosmetic care in rosacea is to restore the balance of the skin, while reducing the underlying inflammation, 
sensitivity, and dehydration. This review aims to highlight the various dermocosmetic care options that 
can reduce discomfort for and bring benefit to patients who have reactive and sensitive skin associated 
with rosacea. Additionally, this report discusses how pharmacists – public health agents – can and should 
offer counseling and support interventions to patients once oral or topical medications are dispensed to 
this pathology.
Keywords: Rosacea/dermocosmetic treatment. Quality of life. Cosmetics. Cosmeceuticals. Skin care. 
Pharmacist advice.
INTRODUCTION
The term “cosmetic” derived from the Greek word 
“Kosmetikos”, which originated from the word “Kosmeo”; 
this word means “to adorn, embellish”. Unquestionably, 
cosmetics are permanently embedded as a part of humanity 
and they are ultimately a reflection of our history. Concepts 
of beauty and appearance have always represented an 
integral part of being a human being. In fact, our earliest 
ancestors used their own bodies for ornamental and 
religious purposes, as reflected in tribal rituals and war 
paintings. In fact, the first records of cosmetic usage were 
found in Egypt (1400 B.C) (Kadunc et al., 2013).
Essentially, cosmetics have long been appreciated 
as science and art. Cosmetics include the preparation and 
use of various products that are designed to embellish 
the skin and its appendages, when topically applied; they 
do not include therapeutic methods that are adopted to 
address issues in the dermis, hypodermis, and other tissues 
(Rodrigo et al., 2010).
Previously, it was believed, that the corneum 
stratum (CS) was an inert biological layer of skin that 
was impenetrable to topical products; however, several 
experimental studies have shown that topical agents can 
alter the skin’s barrier and cutaneous functions (Kadunc 
et al., 2013). Dysfunction in the skin’s ability to act as a 
barrier constitutes an important factor in the pathogenesis 
of inflammatory skin diseases. Research has shown 
the beneficial effects of cosmetics on the physiological 
parameters of the skin’s barrier function. For example, 
the use of moisturizers has demonstrated significant 
improvements in the skin’s overall state, in its level of 
dryness, and in individuals’ quality of life (QOL) (Dreno 
et al., 2014).
Nowadays, the development of cosmetics and body 
care products, known as CB, is regulated in a manner 
comparable to that of medicine; this fact is generally 
unknown to the public and dermatologists (Dreno et al., 
2014).
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In accordance with European legislation, cosmetics 
and body care products (CB) have been subject to 
frequent changes due to the establishment of higher 
requirements set forth by international policies to ensure 
product quality, safety, and efficacy. These policies are 
in place to guarantee consumer rights and to ensure the 
protection of public health. For instance, in Portugal, the 
National Authority of Medicines and Health Products, 
I.P. (INFARMED) is responsible for supervising and 
regulating the CB, ensuring that health professionals and 
consumers acquire high-quality (reliable) and safe CB 
(Santos, 2013; Portugal, 2008). 
According to the Decree Law Nº 189/2008 of 24th 
September (Portugal, 2008), CB is legally defined as 
“any substance or preparation intended to be placed in 
contact with the various external parts of the human body 
(epidermis, hair system and hair, nails, lips and external 
genital organs) or with teeth and oral mucosa, with the 
purpose of exclusively or mainly clean them, perfume 
them, change their appearance, protect them, keep them 
in good condition or correct body odors”. From this 
definition, one can extract that CB are intended exclusively 
for external use (Rodrigo et al., 2010).
There are several classes of cosmetics that have 
incorporated low concentrations of active substances 
that are capable of acting on the structure and functions 
of the skin, and which benefit both the skin and one’s 
general health (Rodrigo et al., 2010). These products that 
do not fall within the definition of traditional cosmetics, 
but which cannot be considered drugs, are called 
cosmeceuticals (the term is an amalgamation of cosmetics 
and pharmaceuticals), dermocosmetics, or active 
cosmetics, as they are developed with the intent of causing 
a differential result in skin care. Thus, a cosmeceutical 
or dermocosmetic product offers therapeutic benefits 
to the skin, but it does not necessarily have a biologic 
dermocosmetic effect (Kadunc et al., 2013). Rather, it 
intersects the areas of medicine and aesthetics (cosmetics), 
while having a great impact on QOL (Guerrero, 2011).
Cosmetics and skin care products have evolved from 
adornment products to treatments that are specifically 
designed to improve the look and feel of the skin; further, 
these products have faced scientific and technological 
advances that allow them to be developed based on 
the consumer’s age, ethnicity, lifestyle, and skin type 
(Dreno et al., 2014). The appearance of one’s skin can 
translate into emotions. Dermocosmetics have thus 
established a new position in dermatology, as they offer 
support to control various phenotypes and skin diseases. 
These products have been developed due to scientific 
advances and the availability of new raw materials, which 
have demonstrated their real utility and function and 
have renewed the current understanding of the normal 
physiology of the skin, as its appearance changes through 
physical changes and biological activity (Kadunc et al., 
2013; Dreno et al., 2014).
As such, dermocosmetics alone or accompanied 
by a pharmacological treatment, are used to improve 
photo protection, dryness or aging skin, and the presence 
of inflammatory diseases such as acne, rosacea, atopic 
dermatitis, psoriasis, seborrheic dermatitis, other skin and 
hair disorders (Dreno et al., 2014); these products meet the 
needs and requirements of the population and contribute to 
increase people’s QOL, sense of humor, and self‑esteem 
(Dreno et al., 2014).
Paying attention to previous considerations, the aim 
of this paper is to examine the current approach to skin 
care and to investigate more appropriate dermocosmetic 
products in rosacea, primarily those available for cases of 
mild rosacea or that serve as a complementary method to 
drug therapy in cases of severe rosacea. Recommended 
cosmetic products and products that are used to avoid this 
illness will be presented, and the importance of patient 
education will be highlighted using the most relevant 
information. Some alternative treatments will also be 
described. 
Pharmaceutical interventions are extremely 
important in rosacea, as they can reduce the physical 
and emotional distress experienced by patients. The 
contribution of the pharmacist in (re) education habits and 
routines can and must be done through counseling.
SKIN BARRIER
The skin is the largest organ of the body; it impacts 
appearance and one’s relationship with others, it serves 
as a protective barrier, and it also acts as a barrier against 
external environmental threats. The skin is composed of 
the epidermis and dermis layers, which are supported by 
a third layer known as the hypodermis (Fernandes, 2012). 
The focus of this paper is to investigate various skin care 
products that are applied to the top layer of the skin, the 
epidermis, which is a protective barrier – and the layer that 
is most affected by rosacea.
The epidermis is a covering epithelium where the 
corneous is the surface layer. Unlike the surface layer, 
the epidermis has no blood vessels; however, diffusion 
occurs through the capillaries in the dermis, which mainly 
consists of keratinocytes (keratin producers) that provide 
permeability and structure, and when they migrate to the 
surface, they stratify, lose their nuclei, and become dead 
keratinocytes (keratinization), forming the cornea barrier. 
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Among these corneocytes, intercellular lipids arranged in 
bilayers are present (Fernandes, 2012; Anunciato, 2011).
In addition to the corneocytes (which are 70%–80% 
keratin), this barrier consists of 20% lipids and 15% water, 
and it is responsible for protecting against internal water 
loss, thereby regulating skin hydration. This barrier is 
covered by a hydro‑lipid film (featuring sebum and sweat, 
respectively, segregated by the sebaceous and eccrine 
glands), which prevents dehydration (Fernandes, 2012).
The natural moisturizing factor (NMF) that is within 
the corneocytes consists of water-soluble and hygroscopic 
substances that absorb water, which is retained in CS 
(Catorze, 2010). Water retention in the NMF through the 
lipid bilayers and the hydrolipid film represents static skin 
hydration. The water coming in from the dermis passes 
through the CS to the skin’s surface, where it evaporates, 
ultimately reflecting the balance between water content in 
the epidermis and the relative humidity of the environment. 
This process is referred to as transepidermal water loss 
(TEWL) and represents the dynamics of skin hydration; 
TEWL is an indication of skin barrier integrity (Anunciato, 
2011; Catorze, 2010). A dysfunctional skin barrier, in 
combination with TEWL increments, causes cutaneous 
dehydration, which characterizes rosacea (Addor, 2016).
ROSACEA
Rosacea is a chronic inflammatory skin disease that 
affects the blood vessels and sebaceous glands, especially 
in the central zone of the face (nose, cheeks, forehead, and 
chin). It is more common in people with light skin, eyes, 
and hair; those of Irish, Scottish, or Northern European 
progeny; and/or those with a family history of rosacea 
(Portugal, 2015). Rosacea may present as lesions in those 
areas that are prone to sun damage, such as the ears, scalp, 
pre‑sternal area, neck, or upper back (Bustínduy, Fumero, 
2016). Persistent or recurrent erythema, papules, pustules, 
telangiectasias, and inflammatory nodules characterize 
this affliction; the reason why rosacea primarily affects the 
face is due to the abundance of sebaceous glands in this 
region (Steinhoff, Schauber, Leyden, 2013), and there are 
also abnormalities in terms of vascular facial reactivity 
and the immune system (Fernandes, 2012). In addition to 
the diversity of clinical manifestations, the etiology and 
pathophysiology of rosacea remains unknown and there are 
no serological or histological markers (Wilkin, et al., 2004).
Even though this is a disease that is not life 
threatening, it still has a negative impact on QOL; 
rosacea patients have a higher probability of experiencing 
depression, social phobia, embarrassment, and stress 
(Moustafa, Lewallen, Feldman, 2014). 
This disease is classified into four subtypes and two 
variants. The subtypes have been distinguished by the 
presence of certain signs and symptoms, which have been 
designated as primary or secondary. A patient can display 
multiple subtypes simultaneously, but the evolution from 
one subtype to another is still controversial; however, 
the American society of rosacea, known as the National 
Rosacea Society (NRS), does not exclude its progression 
(Chauhan, Ellis, 2013; Elewski et al., 2011). The various 
manifestations of rosacea may vary from one individual 
to another, but individuals must present at least one of the 
primary signals and eventually develop some secondary 
signals, so the diagnosis can be implemented (Chauhan, 
Ellis, 2013). The primary signs are flushing (transient 
erythema), non-transient erythema (persistent), papules, 
pustules, and telangiectasias. Secondary signs include 
burning or stinging, plaques, eye dryness, edema, ocular 
manifestations, and phymatous changes (Chauhan, Ellis, 
2013).
In 2002, the NRS created a classification system for 
this condition in order to standardize the diagnosis among 
physicians; according to this system, rosacea is divided 
into its primary and secondary characteristics, as well as 
on the presence of one or more primary features. As far as 
secondary characteristics are concerned, these may or not 
be present, and in some cases, these characteristics may 
appear alone. The combination of two or more secondary 
signals is not sufficient for establishing a diagnosis; as 
such, the 
different subtypes are shown based on different 
rosacea variants and their respective characteristics 
(Fernandes, 2012; Chauhan, Ellis, 2013; Two et al., 2015; 
Barco, Alomar, 2008; Banasikowska, Singh, 2016). 
Subtype I, known as erythemato‑telangiectatic 
rosacea (ETR), exhibits a fine‑textured skin, characterized 
by episodes of flushing that can last more than 10 
minutes; this condition may also present with persistent 
central facial erythema, usually acompanied by stinging 
or burning, and exacerbated when topical agents are 
applied. Emotional stress, hot drinks, alcohol, spicy 
foods, exercise, hot or cold weather, and hot baths can 
cause flushing. Erythema can also be observed in the 
peripheral zone of the face, ears, neck, and upper chest. 
Telangiectasias are common, but not necessary, for the 
diagnosis of ETR. The skin around the eyes is usually 
unaffected. This is considered the most common subtype 
of rosacea. Subtype II, or papulo-pustular rosacea (PPR), 
is the classic presentation of rosacea and it usually occurs 
in middle-aged women. It is characterized by papules or 
pustules distributed in the central face, paranasal, perioral, 
and periorbital areas. In more severe cases, it may progress 
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to chronic facial edema; It is distinguished by the absence 
of comedones. Telangiectasias are less common than 
in subtype I, and flushing is less frequent and severe. 
Periocular edema may be the initial presentation of PPR. In 
more severe cases, it may progress to chronic facial edema; 
this form of rosacea is known as Morbihan’s disease.
Subtype III, or phymatous rosacea (PhR), is 
the predominant form of this condition in men. It is 
characterized by thick skin and an increase in the irregular 
surface nodule holes, which may occur in any sebaceous 
facial area (e.g., the ear, eyelid, chin, or cheeks); the most 
affected is the nose area. ETR or PPR symptoms can also 
be found.
The NRS defines subtype IV, or ocular rosacea, 
by one of the following signs or symptoms: watery 
or red eyes, burning or stinging, eye dryness, itching, 
and photosensitivity; blurred vision, foreign‑body 
sensation in the eye; telangiectasias in the conjunctiva 
and eyelid margins; or by eyelid and periocular erythema. 
Ocular manifestations usually precede any cutaneous 
manifestations, but they can also occur simultaneously. 
Other common symptoms are blepharitis, conjunctivitis, 
irregular eyelid margins, chalazion (eyelid cyst caused by 
inflammation of the meibomian glands), and hordeolum. 
Patients with cutaneous rosacea should be forwarded 
to an ophthalmologist when presenting with ocular or 
conjunctival hyperemia discomfort, ensuring a reduced 
risk of vision loss. This situation affects both sexes, unlike 
facial rosacea (Weinkle, Doktor, Emer, 2015). The different 
subtypes of rosacea are shown in Figures 1, 2, 3, and 4.
Granulomatous rosacea is a rare variant of rosacea 
characterized by papules or hard nodules of reddish color, 
which can turn into scars in severe cases. These lesions 
vary in size among patients, but they are monomorphic in 
FIGURE 1 – Subtype I or erythemato–telangiectatic rosacea 
(ETR), showing central erythema. (Data from: Margalit et al., 
2016). 
FIGURE 2 – Subtype II, or papulo–pustular rosacea (PPR), 
showing papules and pustules. (Data from: Margalit et al., 2016).
FIGURE 3 – Subtype III, or phymatous rosacea (PhR), showing 
thick skin in the nose. (Data from: Margalit et al., 2016).
FIGURE 4 – Subtype IV, or ocular rosacea, showing eyelid 
margin erythema. (Data from: Margalit et al., 2016).
each and situated in the upper part of the face around the 
eyes and nose (Wilkin et al., 2004; Banasikowska, Singh, 
2016) The other variant is fulminant rosacea, a very severe 
and rare form of rosacea, which arises suddenly in young 
women as papules, severe pustules, and nodules with 
cystic formation (Bustínduy, Fumero, 2016). 
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EPIDEMIOLOGY
The number of cases of rosacea is not yet fully 
understood, and several studies in recent years indicate 
that the prevalence of rosacea may vary from 1%–22%, 
depending on the methodology and sample used, making 
it difficult to make comparisons between them. Thus, 
questionnaires administered in the general population 
have the potential to access a larger sample, thus reflecting 
a greater prevalence of the disease, while questionnaires 
administered by dermatologists represent a more limited 
population, showing inferior results (Weinkle, Doktor, 
Emer, 2015). The results indicate that many patients never 
seek a doctor for their condition. It was estimated that 100 
million people have rosacea and that females are the most 
affected, especially during menopause, at a ratio of 2:1 
relative to males (Amsler, 2014). Very common in people 
who are fair skinned (skin types I–II) and have blond 
hair and blue eyes, rosacea affects more than 10% of the 
population in Northern Europe and 4% of darker‑skinned 
people, such as African‑Americans, Latin people/Hispanics, 
and Asians (Fabbrocini et al., 2015). Those between the ages 
of 30–60 years are the most affected. Subtype I (ETR) is the 
most prevalent, followed by subtype II (PPR), subtype III 
(PhR) (which is most common in men over 40 years of age), 
and subtype IV (ocular) which, despite its difficult diagnosis 
(based on the diverse presentation of this condition), is 
the most frequently reported by ophthalmologists, with 
an incidence rate of 6%–72%. Rosacea is considered as a 
dermatological entity, and it may be a more common disease 
than previously suspected (Weinkle, Doktor, Emer, 2015).
PATHOPHYSIOLOGY
The etiology of rosacea seems to be multifactorial; 
in addition to one’s genetic predisposition and skin 
phototype (more common in individuals with a family 
history of rosacea and low phototype skin), which are 
critical for prolonged and exacerbated vascular reactions, 
both environmental and intrinsic factors can trigger 
vasodilatation. These factors, alone or in combination, 
determine the evolution of the dermatosis, acting as triggers 
or aggravating factors of rosacea (See Table I) (Adams, 
Coven, Grippe, 2016; Addor, 2016). As such, rosacea 
is triggered due to chronic exposure to repeated factors, 
particularly those that cause flushing, which include hot 
and cold temperatures, sunlight, wind, hot drinks, exercise, 
spicy foods, alcohol, topical irritants, and menopause (Pelle, 
2012). The skin’s hypersensitivity to thermal, chemical, 
and biological stimuli supports the multifactorial theory 
underlying the etiology of rosacea (Adams, Coven, Grippe, 
2016; Addor, 2016). In fact, the cause of the disease is 
unknown; however, microorganisms, ultraviolet radiation 
(UV), and abnormalities of the immune system are possible 
causes of the disease (Fernandes, 2012). 
The pathophysiological changes contribute to the 
epidermal, dermal, and perivascular inflammation that 
result in skin barrier dysfunction, where the skin is unable 
to attract and retain water. There is an increase in TEWL, 
which translates into dryness and skin sensitivity. This 
increase in TEWL involves the central region of the face, 
and it plays an important role in rosacea subtypes I and 
II. Additionally, the pH of the skin increases and there is 
a loss of antimicrobial function. Clinically, there is a low 
tolerance to topical products such as soaps and substances 
with low pH (lactic acid, retinoic acid, etc.) that results in 
burning, itching, and stinging (Bustínduy, Fumero, 2016; 
Two et al., 2015; Addor, 2016).
DIAGNOSIS
Usually, establishing a rosacea diagnosis is not 
TABLE I – Triggers or intensifiers of rosacea (Data from: Bustínduy, Fumero, 2016)
Triggers or intensifiers Types
Dietary factors
Liver, yogurt, cream, cheese, eggplant, tomato, spinach, lime, white beans, peas, avocado, 
banana, plum, raisins, fig, chocolate, vanilla, citrus, soy sauce, vinegar, spicy and hot foods, 
alcohol, hot beverages, and yeast derivatives.
Emotional Stress, anxiety.
Weather Sun, intense wind, cold, humidity.
Temperature Heated atmosphere, saunas, hot baths.
Cosmetic products and medication Cosmetics and sprays with alcohol. Fragrances. Hydro-alcoholic substances or substances with acetone. Vasodilators and topical corticoids.
Health conditions Menopause, caffeine withdrawal, chronic cough.
Exercise Intense exercise or weight lifting.
Common stingers Acetone, alcohol, propylene glycol, sodium lauryl sulfate.
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difficult (Rodrigo et al., 2010). The term “rosacea” does 
not define a specific clinical condition (Del Rosso et al., 
2014). The recognition of primary and secondary signals 
is the key to accurate diagnosis and the establishment of 
a treatment plan; one or more primary signals must be 
present for diagnosis in the central area of the face (Adams, 
Coven, Grippe, 2016).
Diagnosis is clinical and involves a variety of 
potential manifestations that vary both in terms of 
presentation and magnitude among different patients. 
There are no tests or clinical markers to confirm this 
diagnosis; therefore, observations, clinical history 
(flushing triggers, frequency and duration of those 
triggers, morphology, and temporal course of the lesions), 
and the exclusion of other disorders are of paramount 
importance. Following diagnosis, the management of 
rosacea should be taken to remove or reduce any signs 
and symptoms while using multiple therapies to optimize 
therapeutic outcomes (Barco, Alomar, 2008; Del Rosso 
et al., 2014). 
DIFFERENTIAL DIAGNOSES
Erythema, facial redness, and sensitive or scaly skin 
are characteristics of the ETR subtype; this presentation 
is shared by seborrheic dermatitis, lupus erythematosus, 
other types of photodermatosis, the prolonged use of 
topical glucocorticoids, Asian flushing syndrome (a 
genetic mutation in the enzyme involved in the metabolism 
of ethanol), or niacin intake (vitamin B3) (Chauhan, 
Ellis, 2013; Del Rosso et al., 2013; Wolff, Johnson, 
Saavedra, 2015). PPR may be confused with acne, 
perioral dermatitis, Staphylococcus aureus folliculitis, 
and Demodex folliculorum infestation due to the presence 
of facial papules and pustules (Wolff, Johnson, Saavedra, 
2015).
THE TRIAD OF ROSACEA CARE
The complex and multifactorial pathophysiology 
of rosacea implies that there is a need for an appropriate 
care plan. Thus, a threefold approach is most likely to 
achieve therapeutic success. The triad of rosacea care 
– patient education, skin care, and treatment – involves 
taking into account all of the patient’s needs, instead 
of only focusing on specific symptoms of the disease. 
For example, techniques such as relaxation training, 
cognitive–behavioral therapy, biofeedback techniques, and 
the use of drugs such as antidepressants and beta blockers 
may be important when controlling the emotional factors 
faced by patients with ETR (Elewski et al., 2011).
Patient education
Patient education is essential so that the individual 
can understand the situation and set realistic expectations 
for therapy in terms of magnitude of improvement and 
response (Del Rosso, Baum, 2008). Counseling the patient 
regarding trigger factors and skin care techniques (like 
moisturizing, cleansing, and using sun protection) are 
important steps in the non-pharmacologic treatment of 
rosacea (Two et al., 2015).
Dermocosmetic care
Appropriate skin care (dermocosmetic care) can help 
repair and maintain the integrity of the skin barrier, reduce 
the signs and symptoms of the condition, and increase 
the beneficial effects of medication. They play a central 
role in maintaining remission and symptom relief (Del 
Rosso, Baum, 2008). Dermocosmetic care should take into 
account three goals: ensure adequate hydration and skin 
protection, improve disease manifestations in conjunction 
with medication, and camouflage areas of redness as much 
as possible (Guerrero, 2011).
Rosacea was once called “acne rosacea”, and it 
was frequently confused with acne. Although the two 
conditions resemblance one another, such as in terms of 
the distribution of lesions, papules, and pustules, and its 
responsiveness to tetracycline, rosacea is different insofar 
as it does not feature acne comedones or increments of 
sebaceous secretion. This difference is very important 
because the products used for oily (acne‑prone) skin are 
generally not suitable for rosacea. As such, one should 
avoid using astringent formulations and sebum regulators 
(Guerrero, 2011; Oliveros, 2012).
There are many cosmetic formulations that dry and 
irritate skin that is prone to rosacea; this is possibly due 
to skin barrier dysfunction or vascular hyper‑reactivity 
(Pelle, Crawford, James, 2004). The skin’s sensitivity can 
increase not only because of exposure to many hygienic 
products, but also based on how these products are applied 
to the skin. The symptoms of sensitive skin tend to be 
more common and more severe in patients with ETR, 
although patients with untreated PPR report symptoms 
such as stinging and burning (Del Rosso et al., 2013). 
Improper skin care can cause or worsen the visible signs 
and symptoms of PPR and ETR. Issuing a warning to 
avoid these skin care products is appropriate for these 
patients. Astringents, toners, menthol, and camphor are 
examples of such products (Pelle, Crawford, James, 2004); 
therefore, an adequate selection of skin care contributes 
to improvements for both subtypes (Levin, Miller, 2011). 
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The skin’s barrier function in rosacea patients is 
interrupted; these individuals have sensitive skin and 
flushing occurs easily. Burning, stinging, and itching are 
common and motivated by this dysfunctional barrier. The 
CS is composed of corneocytes, which are kept together 
by desmosomes and an intercellular lipid membrane, 
including physiological lipid‑regulating TEWL. Proper 
skin care can help repair and maintain the lipid membrane 
of the epidermal barrier (Del Rosso, Baum, 2008), which 
includes a gentle facial cleanser and moisturizer, or a 
cutaneous barrier repair product, respectively; these 
products have demonstrated their ability to improve 
therapeutic outcomes while reducing skin irritation in 
patients undergoing medical therapy. There are no large-
scale comparative studies of patients with rosacea that 
specifically recommend which dermocosmetic products 
must be used. However, facial cleansing and moisturizing 
should be selected based on their ability to repair and 
maintain the permeability of the CS, to increase hydration, 
and to reduce the likelihood of skin irritation. Moreover, 
these products are cosmetically pleasing and they do not 
contain additives that tend to induce allergic or irritant 
contact dermatitis (Del Rosso et al., 2013). However, there 
is a lack of scientific evidence on the use of skin cosmetics, 
and the associated results are relative when promoting 
rosacea treatment or reducing flushing symptoms (Del 
Rosso et al., 2013). 
The final purpose of treatment is to restore the 
skin’s balance by limiting the dilation of blood vessels 
and inflammation, reducing skin sensitivity, and offsetting 
dryness. Below, the most important type of care that should 
be adopted by patients with rosacea is discussed.
Cleanser – the importance of a smooth agent
A cleanser that can be used in combination with 
topical therapy (if any), while simultaneously remaining 
biocompatible with the skin’s conditions, must be 
recommended (Mukhopadhyay, 2011). Ideally, a cleanser 
removes dirt, grease, environmental pollutants, and 
harmful skin bacteria without changing or removing 
the lipids, proteins, and normal flora that contribute to 
its integrity (Levin, Miller, 2011). A cleanser works as 
a surfactant with affinity for the water phase (polar) and 
oil phase (non-polar), reducing the tension within the 
skin, a swell as between dirt (non‑polar) and water, while 
removing dirt with cleaning actions (Draelos, 2014).
Despite being effective at cleansing the skin, an 
aggressive or abrasive cleanser damages the CS when it 
removes lipids, proteins, and NMF. In PPR and ETR, use 
of these agents compromises the permeability of the CS 
and sensitive skin; it is advisable that soft cleansers be 
used, as they will not exacerbate this condition (Levin, 
Miller, 2011).
Some compounds make for aggressive cleansers, 
such as surfactants that are combined with keratin 
to promote its denaturation, resulting in damage to 
keratinocyte cell membranes and leading to dermal adverse 
responses. The surfactants are divided into four groups 
(anionic, cationic, amphoteric, and non-ionic), according 
to their molecular charge, or lack thereof. Anionic agents 
are those with the greatest potential to irritate the skin, 
although they can be combined with a cationic or nonionic 
surfactant, which affect the potential of these agents to lead 
to irritation. These agents are commonly used, even in 
the mild cleansers, due to their excellent foaming ability. 
Cationics have excellent antimicrobial properties. The 
type and amount of surfactant influence the potential for 
irritation and dryness. Therefore, the irritation potential 
of a given cleanser may increase, if left longer on the 
skin (waste cleanser or rinse factor). The maintenance of 
the skin surface pH (4–6.5) during cleaning prevents the 
growth of certain microorganisms (pH cleanser) (e.g,. 
syndets and cleansing lotions have a neutral or slightly 
acidic pH, which corresponds to the skin pH) (Levin, 
Miller, 2011; Mukhopadhyay, 2011).
The importance of soft cleansers with simple 
formulations in the control of rosacea and other sensitive 
skin conditions has spurred the development of therapeutic 
soft cleansers; these agents offer delicate cleaning without 
removing the functional components of the skin (Levin, 
Miller, 2011). There are several types of cleaning products, 
such as soaps, which are mixtures of fatty acid esters with 
good emulsifying properties that produce enough foam, 
but are not suitable for rosacea because they are alkaline 
(pH 9–10) and can either destroy the superficial lipid layer 
of the skin or they can worsen the skin’s barrier function, 
leading to excessive dryness (an effect called “soap”) (Del 
Rosso, Baum, 2008; Pinheiro, Pinheiro, 2007). Soaps 
are excellent at removing dirt and grease, but they are 
aggressive cleansers; when they remove the beneficial 
lipids and proteins, they hinder the CS’s ability to increase 
TEWL, resulting in dehydration, scaling, and penetration 
of topical products, and leading to greater sensitivity and 
more irritated skin (Levin, Miller, 2011). Syndets, also 
called synthetic detergents, dermatologic pains, or “no-
soap soaps”, are less irritating, as they reduce dryness in 
the skin and have a pH that is neutral or slightly acidic 
(between 5.5–7); these agents are more compatible with 
the natural acidity of the skin. They are available in solid or 
liquid form. The solids are syndet bar cleansers, where the 
liquid phase is reconstituted by the addition of water and 
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they have an excellent tolerance (Del Rosso, Baum, 2008; 
Pinheiro, Pinheiro, 2007). Combars feature a combination 
of soap, syndet bars, and an antibacterial agent with an 
alkaline pH (9‑10). Although their antibacterial power 
reduces harmful bacteria, these agents can eradicate the 
normal flora of the skin and increase dryness and irritation. 
Patients with rosacea already have an imbalance of flora, 
as well as sensitivity and dryness issues, thus rendering 
the combars unsuitable for this condition (Levin, Miller, 
2011). Combars are softer than soaps, but they provide 
more thorough cleaning than syndets (Mukhopadhyay, 
2011). Cleansing lotions (cleansing creams or milks) 
are rather smooth cleansers that free lipids, do not form 
soap, and leave a thin film of moisturizer on the skin 
(Levin, Miller, 2011); they do not require water for its 
elimination and they contain emollients and/or humectants 
that counter the potential dryness or irritation of the 
surfactant. These agents have a slightly acidic or neutral 
pH that is compatible with the skin’s pH. Cleansing foams 
are also appropriate for rosacea (Del Rosso, Baum, 2008). 
Cleansing waters are used to remove cleansing lotions. 
They contain detergents, humectants, and thermal water 
that is typically applied with cotton; cleansing water is 
suitable for reactive skin types (Levin, Miller, 2011).
In summary, syndets or cleansing lotions are the 
most suitable skincare agents in the treatment of rosacea, 
as they have less potential for irritation. Both cleansing 
agents can deposit beneficial ingredients to the skin 
despite the short contact that they make during cleaning 
and rinsing (Levin, Miller, 2011). Therapeutic cleansers 
contain 10% sodium sulfacetamide and 5% sulfur, which 
are approved for the treatment of rosacea. The single 
contraindication is hypersensitivity to sulfonamides, 
sulfur, or other components (Mukhopadhyay, 2011). 
These cleansers can be identified by the fact that they have 
the terms “balanced pH” or “suitable for sensitive skin” 
written on the label (Draelos, 2014).
The application of these cleansers should be done in 
a smooth manner, without rubbing or friction, to prevent 
redness and burning. It is difficult to impose a skin 
cleansing routine on some individuals, as some cleanse 
their skin in the shower, and others just refuse to clean 
their faces with water (Deshayes, 2014). The pharmacist 
needs to adapt to different situations and should advise on 
the least aggressive gestures. The application of a syndet 
should be done with the fingers using circular and smooth 
movements in the face, and this agent should be rinsed 
with warm water. For makeup removers that do not require 
rinsing (lotions), the gestures are the same, and the product 
should be eliminated using a makeup‑removing cotton 
ball. In both cases, cleaning is followed by the application 
of thermal water (which has a soothing effect) or micellar 
water, but this is less effective for cleansing areas of 
embossed injury (e.g., papules and pustules) (Deshayes, 
2014). Thermal water sprays should be regularly used 
among these patients; tap water, if applied on the face, 
should be tepid and any changes in temperature should 
be avoided (Guerrero, 2011). Technological advances 
have enabled the creation of new soft cleansers that 
provide moisturizing benefits; these properties allow these 
cleansers to be used in various dermatologic disorders, in 
parallel with topical therapy, thereby influencing disease 
outcomes and progression (Mukhopadhyay, 2011). 
Examples of various cleanser compositions are noted in 
Table II.
Cutaneous moisturizer or emollient
After cleaning the skin, hydration is important for 
restoring the skin’s barrier. Moisturizers do not treat the 
barrier function; rather, they create an environment that is 
conducive to skin recovery (Draelos, 2014). Moisturizing 
is a word of Greek origin, which means “add water” or 
“combine with the water” (Catorze, 2010). Emollient 
is a word that is derived from the Latin term emolliens, 
whose verb is emollire and means “soften” or “smooth”. 
Moisturizers are topical substances that make the skin 
smooth and soft. Regardless of how they operate, the 
emollient effect is common to all substances that contribute 
to the skin’s hydration (i.e., moisturizers and emollients) 
(Catorze, 2010; Pinheiro, Pinheiro, 2007).
Daily use of a hydrant is important for reducing a 
dysfunctional epidermis, which acts by increasing the 
water content of the skin at the CS level (Catorze, 2010; 
Del Rosso, Baum, 2008). Moisturizers contain lipids 
that soften and restore elasticity and homeostasis in the 
skin, avoiding the TEWL, to leave a lipid film that fills 
the spaces between the corneocytes and facilitates its 
accession to the CS level (Pinheiro, Pinheiro, 2007).
Cutaneous moisturizers work on the skin’s protective 
TABLE II – Example of a cleanser composition (Data from: 
Mukhopadhyay, 2011)
Water Fillers (hardeners)
Surfactants Preservatives (inhibit 
microorganisms)
Moisturizers (for hydration) Fragrance (mask surfactant 
odor)
Binders (stabilizers) Pigments (in some)
Lather enhancers (in some)
Dermocosmetic care for rosacea
Braz. J. Pharm. Sci. 2017;53(4):e00182 Page 9 / 16
barrier in many ways (Catorze, 2010; Del Rosso, Baum 
2008; Levin, Miller, 2011). First, it is occlusive, preventing 
the evaporation of water (e.g., silicates, petrolatum, 
mineral oil, lanolin, and silicone derivatives). It is also 
humectant; it captures and sets internal and/or external 
water levels by increasing the skin’s hydration and 
facilitating increased penetration of topical pharmacologic 
agents; examples include glycerin, propylene glycol, 
sodium lactate, hyaluronic acid, urea, lactic, glycolic 
and tartaric acids, and sorbitol, among others; glycerin 
is the most widely used and one of the most effective 
humectants, but high concentrations can result in clammy 
skin after application. Mixed products compensate for 
lipid deficiency, repair the skin’s barrier function, and aid 
in water regulation (Levin, Miller, 2011; Mukhopadhyay, 
2011).
Moisturizers exist in two formulations: oil in water 
emulsions (O/W), where water is the dominant phase; 
these agents are more fluid and less oily and are normally 
used in day creams. These moisturizers are characterized 
by a fresh feeling and non-glossy appearance. The day 
moisturizers are generally composed of mineral oil, 
dimethicone, propylene glycol, and sufficient water to 
form a cream or lotion. Water in oil emulsions (W/O) in 
which the oil is the dominant phase are greasy and more 
occlusive emollients. Normally used as night creams, they 
are identified by a warm feeling and shiny appearance; 
night moisturizers are comprised of mineral oil, acetylated 
lanolin, petrolatum, and water to form a cream (Draelos, 
2014; Pinheiro, Pinheiro, 2007).
Moisturizers should have the maximum possible 
purity to limit the risk of irritation, and they should be 
devoid of fragrance and alcohol. Actives are multiple 
and often combined. They are divided into three classes: 
smoothing, vessel protective, and anti‑inflammatory. The 
components that reinforce the skin barrier and favor the 
water reserve in the epidermis are caused by classical 
components such as glycerin, Karité butter, and others. A 
low degree of irritants (Deshayes, 2014) (lactic, glycolic, 
and salicylic acids, or retinol), which may be part of 
anti-aging moisturizers, are discouraged in rosacea (i.e., 
it is preferable to opt for basic moisturizer formulations) 
(Draelos, 2014). 
Overall, formulations that contain astringents and 
abrasives, and which can exacerbate the symptoms of 
rosacea, must not be used. A list of light and moderate 
irritants that can foster potential skin irritation to a patient 
with rosacea is presented in Table III. It is the absence or 
presence of low concentrations of these potential irritants 
that contributes to the smoothness of the formulation 
(Levin, Miller, 2011).
Cutaneous moisturizers are the most frequently 
prescribed products in dermatology and they are 
considered to feature equal therapeutic and cosmetic 
action; hence, these agents fall under the group of 
cosmeceuticals (Catorze, 2010).
Sunscreen
Sun protection covers two objectives: it ensures 
the required photo-level protection in all individuals and 
decreases the exacerbation of signs and symptoms induced 
by sun exposure in patients with rosacea (Guerrero, 
2011). Considering that ultraviolet (UV) radiation can 
trigger rosacea, it is recommended that patients use a 
daily product containing a sun protection factor (SPF) 
level higher than 50+ to prevent the destruction of the 
dermis induced by UV radiation. It is recommended 
that patients use formulations that are able to filter out 
UV‑A and UV‑B radiation (Del Rosso, Baum, 2008; 
Portugal, 2015). Physical or mineral filters with titanium 
dioxide and zinc oxide are well tolerated, but hardly 
accepted, because after application, they leave a white 
layer on the skin (Elewski et al., 2011; Deshayes, 2014). 
Despite this situation, these filters should be preferred 
due to their simple formulation, which provides them 
with a high level of tolerability (Guerrero, 2011). The 
sunscreen must be able to be spread, smoothly, over the 
face without oiliness, and while maintaining the potency 
TABLE III – Substances that induce mild and moderate cutaneous 
stinging (Data from: Draelos, 2014)
SLIGHT STINGERS
Benzene 
Phenol 
Salicylic acid 
Resorcinol 
Phosphoric acid
MODERATE STINGERS
Sodium carbonate 
Trisodium phosphate 
Propylene glycol 
Propylene carbonate 
Propylene glycol diacetate 
Dimethylacetamide 
Dimethylformamide 
Dimethylsulfoxide 
Diethyltoluamine 
Dimethyl phthalate 
2‑Ethyl‑1,3‑hexanediol 
Benzoyl peroxide
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and duration of photoprotection (Guerrero, 2011). In this 
regard, components such as silicones should be included 
to minimize stinging and erythema. In cyclomethicone or 
dimethicone forms, silicones are non‑irritating; act as non‑
acnegenic occlusive agents, which delay TEWL; confer 
water resistance to cosmetics; and are easily spread on the 
skin (Pelle, Crawford, James, 2004).
However, no sunscreen is able to avoid the unpleasant 
sensation of infrared radiation, which accentuates feelings 
of redness and burning. It is ideal for patients to use wide-
brimmed hats and sunglasses (Deshayes, 2014); sunscreen 
can serve as a makeup primer.
Corrective makeup
Some patients want to use cosmetics that mask 
erythema, telangiectasia, papules, and pustules, which 
are less visually attractive (Del Rosso, Baum, 2008; 
Draelos, 2001). In the case of a man or a woman, a 
medical appointment should not end without a makeup 
prescription, which must be offered as a complement to 
treatment, since the concept of QOL in this condition is 
essential for ensuring that the injuries disappear and bring 
clinically visible results, in accordance with some authors’ 
findings. Therefore, this dermatologic or corrective 
makeup (CM) is defined as a therapeutic bridge to achieve 
positive and visible results (Deshayes, 2014). The CM 
uses the principle of color opposition (Figure 5), in which 
pigments are designed to match the normal color of the 
patient’s skin, while covering the underlying lesions or 
redness. Thus, erythema is offset with green pigments, 
which neutralizes the red color and is easily camouflaged. 
The mixture of red skin with a green broker foundation 
produces a brown tone that is covered by a conventional 
foundation (Draelos, 2001). Examples of CM applied on 
ETR and PPR patients are shown in Figures 6 and 7. 
The makeup used in rosacea care must meet certain 
characteristics (Deshayes, 2014). For instance, very red 
lesions require the use of specific products with a large 
amount of pigments; application and removal must be made 
with extreme softness, particularly when there is active 
inflammation. The product must also be rich in pigments 
to achieve maximum coverage (these products contain 5–8 
times more pigment than a single foundation), but they 
should also be easy to spread. As is the case with sunscreen, 
this strong pigment load offers the ability of partially 
protecting the skin from sunlight. Additionally, a compatible 
moisturizer should precede the application of this makeup; 
otherwise, it forms a type of fuzz on the skin. There are no 
moisturizing properties in the CM; rather, it only offers 
camouflage and a powdered appearance (Deshayes, 2014).
CM is presented in different formats: fluid 
formulations, creams, compact creams, sticks, and 
powders. These products cannot be irritating or 
allergenic; they should not contain perfume, should not 
be comedogenic or acnegenic, and they must be clinically 
tested. In inflamed skin, these products should avoid 
any friction that accentuates the erythema and renders 
makeup application an unpleasant process. These cosmetic 
products should be applied to the injury by gently tapping 
the skin with one’s fingers (Deshayes, 2014; Draelos, 
2001).
Cleaning the skin to sanitize it (without leaving 
any specks that may affect the process of neutralization), 
hydrating the skin according to skin type, neutralizing the 
lesions with a green color corrector, choosing the most 
suitable foundation tone for the skin’s photo type while 
applying it with a soft touch (with the third finger or a 
sponge), and applying a powder to set the makeup are 
included in CM process (Parada, Teixeira, 2008).
The aforementioned products, with their many 
constituents, rarely contain no irritating solvents; they are 
more difficult to apply and remove, so their use must be 
avoided. Thus, formulations with a simple composition, 
and which can be adjusted with a powder containing 
protection against UV-A and UV-B, are recommended 
(Pelle, Crawford, James, 2004).
Treatment
There is no cure for rosacea, but the use of different 
methodologies helps to reduce symptoms and the spacing 
of crises, and it helps to improve its aesthetic aspect 
(Fernandes, 2012). Fortunately, there are many available 
FIGURE 5 – The principle of color opposition used in corrective 
makeup, which shows that green neutralizes red. (Data from: 
Guerrero, 2011).
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treatments that can provide relief to the patient when used 
correctly, and in accordance with the clinical presentation. 
Any treatments used for this chronic inflammatory 
condition must meet the following objectives (Elewskiet 
al., 2011; Weinkle, Doktor, Emer, 2015): relieving signs 
and symptoms through fast‑acting treatments; delaying 
or preventing the development of more advanced stages 
of the disease; maintaining the state of remission and 
preventing exacerbations by prolonged therapy to prevent 
relapses; keeping the skin in the best possible condition; 
and improving the patient’s QOL. The strategies employed 
in clinical treatment, though not curative, can effectively 
reduce inflammatory lesions and facial erythema, 
particularly perilesional erythema (Del Rosso, Baum, 
2008). The situations of mild to moderate rosacea (ETR or 
PPR) can be treated by over‑the‑counter (OTC) products 
and, in most cases, it is not necessary to resort to drug 
prescriptions (oral or topical therapy) (Portugal, 2015). 
In cases where therapy is necessary, topical agents are 
used for acute flares (erythema and inflammatory lesions), 
but they are primarily used to maintain remission states. 
Selecting between the different dosage forms depends 
on the skin type and the area to be treated; for example, 
creams are preferable in damp areas, while lotions are 
more suitable to the scalp. Compared with oral treatments, 
topical agents have fewer side effects and a lower tolerance 
level. However, the effects are slower at the beginning, 
resulting in a longer period before any desired results are 
achieved (Adams, Coven, Grippe, 2016). 
Regarding topical therapies, the only US Food 
and Drug Administration (FDA)-approved agent 
for persistent erythema is brimonidine tartrate gel. 
Furthermore, treatments for PPR include metronidazole 
and azelaic acid (available in a variety of strengths 
and formulations). Some authors consider these agents 
beneficial for PPR, while the combination between 
pimecrolimus, oral treatments, and/or vascular therapy 
is suitable for ETR, despite the fact that these agents are 
non-FDA-approved therapies. To reduce papulo–pustular 
lesions, some of the non-FDA-approved treatments 
include benzoyl peroxide and antibiotic combinations 
(e.g. BP–clindamycin). In addition to the potential 
irritation associated with these agents, there are limited 
published data on sodium sulfacetamide 10% + sulfur 5% 
cleanser (which is also malodorous); this formulation has 
shown efficacy for the treatment of inflammatory lesions 
FIGURE 6 – Before and after applying corrective makeup in an erythemato–telangiectasic rosacea patient. (Data from: Deshayes, 
2014).
FIGURE 7 – Before and after applying corrective makeup in a papulo‑pustular rosacea patient. (Data from: Deshayes, 2014).
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and facial erythema in a previous investigation (Weinkle, 
Doktor, Emer, 2015). 
In cases of moderate to severe rosacea (PPR and 
ocular rosacea), and in addition to skincare and skin 
cosmetics (non-pharmacological treatments), oral therapy 
is typically used. Oral therapies are administered to reduce 
inflammation, papules, and pustules (Adams, Coven, 
Grippe, 2016; Portugal, 2015). Regarding oral therapies, 
the only FDA‑approved option for PPR is the modified‑
release doxycycline (40 mg daily), which provides 
anti‑inflammatory effects with sub antimicrobial dosing. 
Oral doxycycline, as well as minocycline with azelaic 
acid or metronidazole, improves inflammatory lesion 
counts. Macrolides, metronidazole, and oral isotretinoin 
are non‑FDA‑approved systemic therapies for PPR. Oral 
isotretinoin is reserved for severe cases of all rosacea 
subtypes (Weinkle, Doktor, Emer, 2015).
Laser therapy is effective for reducing erythema and 
telangiectasias, as their targets are the blood vessels. In 
rosacea, the following can be used: IPL (intense pulsed 
light laser) or PDL (pulsed dye laser). IPL allows for the 
removal of abnormal vessels, reducing inflammation and 
restructuring the collagen in the skin (Adams, Coven, 
Grippe, 2016). Surgical treatments are used for PhR 
due to thickening of the skin, in order to standardize the 
nose edges while offering minimal scarring, if possible 
(Fernandes, 2012). Vascular lasers, together with oral 
isotretinoin treatments, are beneficial for patients with 
multiple subtypes of rosacea (Weinkle, Doktor, Emer, 
2015). 
Alternative treatments
There are plant-based substances that can be used to 
reinforce the walls of the blood vessels, modulate vessel 
motricity, and reduce perivascular edema. Additionally, 
the anti-softener and anti-irritant effects improve 
tolerability and compliance to topical pharmacotherapy. 
Dermocosmetic products have earned a prominent place 
in the control of dermatological procedures, especially 
following vascular laser therapy; these products help to 
improve the visibility of superficial blood vessels, which 
are targets of this therapy, and they induce healing days 
after the procedure (Guerrero, 2011).
Creams that feature liquor ice, grapeseeds, golden 
chamomile, and horse chestnut have vasoconstrictor 
properties that reduce erythema and telangiectasia 
(Lemmel, 2009). Green tea reduces the papules and 
pustules; conversely, niacinamide (in vitamin B3 form) 
improves the function of the skin barrier and reduces 
redness. Aloe vera and chamomile reduce irritation and 
inflammation, respectively. These natural therapies require 
further clinical trials, as they may induce adverse effects, 
especially when combined with prescribed medication 
(Adams, Coven, Grippe, 2016).
Research has been identifying several active 
ingredients that can provide relief and increase comfort 
to patients with telangiectasias; as such, floral waters 
(e.g., witch hazel, orange blossom, or cherry laurel) 
are recommended to soothe the reactive skin of rosacea 
patients. Nowadays, interest is primarily focused on 
flavonoids, which have vasculotropic and antioxidant 
effects. The long list of flavonoids include hesperidin 
methyl chalcone; Vitis vinifera; Centella asiatica and 
Melilotus officinalis stimulate microcirculation; Ruscus 
aculeatus with anti-edema action and a microcirculation 
protector; Vaccinum mirtilus, which reduces capillary 
fragility; Ginko biloba; and licorice extract, which acts as 
an anti‑irritant (Guerrero, 2011; Lemmel, 2009), among 
others.
SOCIAL AND PSYCHOLOGICAL IMPACTS 
OF ROSACEA
ETR is one of the subtypes of rosacea that is 
frequently misunderstood and sometimes associated 
with alcohol, particularly when considering the onset of 
blushing, which creates a very negative effect on social 
relationships (Guerrero, 2011). Patients with rosacea 
may experience low self‑esteem, feelings of frustration, 
embarrassment, worry, and more limited social relations 
due to their condition, thus compromising their QOL. 
Strategies for managing rosacea must be focused on the 
psychological impact of this condition while improving 
physical manifestations (Elewski et al., 2011). Patients 
who are knowledgeable about their condition deal 
better with possible complications or relapses. Studies 
indicate that emotional health is typically restored 
when the symptoms are successfully treated (Nordqvist, 
2016). In turn, this success is more likely if the patient 
adheres to the treatment prescribed by the doctor, and if 
appropriate measures are taken (such as using the correct 
dermocosmetic products, and applying them with the 
proper gestures) to minimize the factors that aggravate 
this condition. It is essential that health professionals 
assess their patients’ QOL using a fast and simple tool like 
the Dermatology Life Quality Index (DLQI). The DLQI 
consists of 10 questions, where the answers consist of 
“not at all”, “a little”, “a lot”, and “very much”, to assess 
how the individual’s skin condition in the last week had 
an impact on his or her day-to-day life (Adams, Coven, 
Grippe, 2016).
Dermocosmetic care for rosacea
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PHARMACEUTICAL INTERVENTION
The main objective of pharmaceutical interventions 
in rosacea is to reduce the physical and mental discomfort 
for the patient (Portugal, 2015). The pharmacist can 
observe the ETR as the first stage of rosacea and provide 
the patient with advice about general hygiene and skincare; 
the doctor must warn against the use of exfoliating 
products, as the skin is thin. Moreover, photosensitizing 
products are also contraindicated, as they contain perfumes 
and acidic substances. For cleansing purposes, products 
without alcohol, detergents, and parabens should always 
be recommended (Oliveros, 2012). 
In situations of moderate to severe rosacea, 
and in addition to skincare and skin cosmetics (non‑
pharmacological treatments), the patient should be 
advised to consult a doctor to evaluate the situation, who 
can then prescribe the most appropriate treatment. Any 
oral medications must be discontinued if the patient has 
any symptoms such as headaches, dizziness, arthralgia, 
myalgia, gum discoloration, or gray skin color that can 
be confused with persistent bruising or symptoms of 
hypersensitivity, such as hives. The use of artificial tears 
and adequate daily cleansing eyelashes in the treatment 
of ocular rosacea are recommended, particularly in 
conjunction with oral antibiotics (Portugal, 2015). To help 
reducing the thickness of meibomian gland secretions 
and promote their expression, hot compresses could be 
applied to the eyelid margins. Applying light pressure 
to the eyelids can help gland expression. Nonpreserved 
artificial tears are the most suitable due to the frequency 
of application and should be applied abundantly all the 
time. (Kharod‑Dholakia, 2017). 
In order to improve patients’ QOL and well‑being, 
there are gestures and dermocosmetic products that the 
pharmacist should recommend, so as to reduce discomfort 
and improve one’s aesthetic appearance (Portugal, 2015; 
Nordqvist, 2016; Portugal, 2010). Moreover, they should 
create a list of foods and beverages that may cause or 
intensify the condition, and which and can aggravate 
rosacea flare‑ups. Some recommendations could be given 
to the patient, such as cleaning the skin twice a day with 
suitable products, and drying the skin gently with a soft 
cotton cloth without rubbing. The patient should void 
harsh abrasives, select soft products that are tailored to the 
patient (and that do not exert astringent action), and avoid 
alcohol, soap, parabens, fragrance, and oil components. 
The patient should remain well hydrated, as dehydration 
can increase and trigger inflammatory processes in 
the cells, thereby altering the structure of the various 
layers of the skin. Use creams whose high tolerance 
reinforces the skin barrier; spray the face with thermal 
water, which is rich in elements and have a soothing 
action; use anti‑inflammatory, antioxidant, healing, and 
moisturizing products that feature vasoprotective action, 
anti-reddening, decongestant, and soothing properties 
(e.g., vitamin C, escin, Ruscus extract, ginseng, ginkgo 
biloba, dextran sulfate, and rhamnosides), which operate 
at the microcirculatory level to strengthen the wall of 
blood vessels (Portugal, 2015; Oliveros, 2012). Additional 
advice must be transmitted, including the use of daily 
sunscreen throughout the year (particularly those with 
UVA/UVB solar filters and an SPF of 50+). In cases of 
intense sun exposure, sunscreen application must be 
performed about 30 minutes before sun exposure and 
repeated every 2 hours. After the application of topical 
medication, the patient must wait at least 10 minutes 
before applying any products. The products should be 
applied in the following order: moisturizer, sunscreen, and 
makeup, if the individual wishes to apply it. CM should 
be used before applying the remaining makeup; makeup 
should always be removed before bedtime, and creams 
or appropriate treatments should also be applied. In the 
winter, patients are urged to wear a scarf to protect their 
faces. Any action that reduces one’s stress levels will help 
prevent crises and exacerbations of existing symptoms. 
These actions may include low‑intensity exercises, like 
walking or swimming; healthy eating; and sleeping at least 
7 hours (Portugal, 2015; Nordqvist, 2016; Portugal, 2010). 
Patients should also introduce foods into their diets that 
are anti‑inflammatory in nature, such as vitamin B, ginger, 
turmeric, omega 3, and olive oil (Adams, Coven, Grippe, 
2016). For men who shave, it is preferable that they use 
an electric shaver instead of the blade. The patient cannot 
apply the product in the periocular area, or near mucous 
membranes or other sensitive areas, unless medically 
indicated. If used, the product must be applied in a thin 
layer, as the amount of product is not synonymous with 
faster, more visible results. Of note, patients should wash 
their hands after applying the product (creams, gels, or 
emulsions), and they should only apply the product to 
affected areas, given that application to other areas can 
cause skin irritation. In the event of accidental contact with 
the eyes, the patient should rinse his/her eyes thoroughly 
with water and, if necessary, go to a doctor (Portugal, 
2015). 
With respect to the support to avert prescription 
drugs, the pharmacist must recommend to the patient about 
the needing of going to the pharmacy at least monthly, 
because the therapy can be followed up and improvements 
evaluated in accordance with the purpose of doctor, in 
terms of dosage and location (Portugal, 2015). Most 
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patients respond well to treatment, but improvements are 
gradual and must be carried out for three months or more 
to visualize the results. Patients should be alerted to this 
situation, and they should also hold realistic expectations 
of their treatment to increase adherence to therapy. 
Moreover, patients should receive follow‑up or tracking 
within 4 weeks after the initiation of therapy, so as to 
check the progress and tolerability of their treatment. After 
the desired control is achieved, the patient can undergo 
follow-up every 3–6 months for reevaluation. At each 
follow-up the pharmacist must evaluate the success of 
the current treatment and consider alternative therapies, if 
necessary; offer instructions to the patient regarding skin 
care and exacerbating factors; and provide support to the 
patient based on that individual’s specific and unique needs 
(Adams, Coven, Grippe, 2016). 
In short, is of vital importance that the pharmacist 
alerts the patient of all the advice abovementioned in 
order to help treatment to be more effective, as the basis 
of treatment lies in avoiding the factors that can aggravate 
the symptoms (Fernandes, 2012). 
CONCLUSION
Rosacea is a problematic, common, difficult to 
control disease that affects a large number of patients who 
require long-term treatment. Much remains unclear about 
the etiology and pathophysiology of rosacea (Elewski et 
al., 2011).
The treatment of rosacea is still a challenge despite 
the various therapeutic options that are currently available. 
Providing comprehensive patient education to manage 
one’s expectations of future results; similarly, offering 
information on skincare and the use of available therapies 
optimizes therapeutic success. Patient education and 
dermocosmetic advice should be highlighted, as they play 
an essential role in the control of this complex and chronic 
disease (Elewski et al., 2011).
The present studies show the importance of proper 
skincare in individuals with rosacea; they also highlight 
how signs, symptoms, and skin irritation can be reduced 
(which can also be caused by the use of topical treatments), 
especially during the first week of application. Galenic 
investigations, made possible to produce rosacea-
appropriate textures containing a limited number of 
ingredients and little or none fragrances or preservatives, 
which provide camouflage of lesions and redness, and 
are sufficiently fluid to be scattered and removed, without 
difficulty (Guerrero, 2011). However, the idea of achieving 
an ideal, universal, single complexion is utopian and 
impossible to achieve due to variations in skin type and 
cultural differences in what are considered aesthetically 
acceptable or desirable facial appearances (Elewskiet al., 
2011).
There are times when medical consultations result in 
poor communication with the patient (Del Rosso, Baum, 
2008; Levin, Miller, 2011); as such, the pharmacist is the 
closest and most appropriate healthcare professional to 
complement and deepen any information that is provided. 
There is no doubt that adopting a dermocosmetic approach 
is crucial in controlling rosacea; this option must be 
considered for all patients, as it modulates the skin’s 
quality and function.
In Europe and the United States of America, the 
category of dermocosmetics/cosmeceuticals is not 
recognized, as there has been a lack of validation of this 
class of products using standard methods. There are only 
reports of these “barrier products” that may result in 
future directives (Rodrigo et al., 2010). The guidelines 
for testing cosmetic products will continue to evolve, 
and it is essential that safety and efficacy trials are carried 
out under rigorous methodologies in accordance with the 
latest adopted guidelines that can be reproducible and 
scientifically valid (Dreno et al., 2014).
In brief, for dermocosmetic care and – more 
precisely – for the careful choice of products for 
rosacea management, the watchword to reiterate is 
“simplicity”. Patients with rosacea should seek safety in 
their formulations of choice (i.e., it should contain few 
ingredients, and it should also be carefully selected and 
dermatologically tested). Patients should also use and 
apply makeup following use of a simple and effective 
dermatologic (if desired), given their sensitive and reactive 
skin condition. 
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Margalit A, Kowalczyk MJ, ŻAba R, Kavanagh K. The role 
of altered cutaneous immune responses in the induction and 
persistence of rosacea. J Dermatol Sci. 2016;82(1):3‑8.
Moustafa F, Lewallen RS, Feldman SR. The psychological 
impact of rosacea and the influence of current management 
options. J Am Acad Dermatol. 2014;71(5):973‑980.
Mukhopadhyay P. Cleansers and their role in various 
dermatological disorders. Indian J Dermatol. 2011;56(1):2‑6.
Nordqvist C. Rosacea: causes, symptoms and treatments. [citad 
2016 Jun 9]. Available from: http://www.medicalnewstoday.
com/articles/160281.php. 
Oliveros AM. Rósacea, cuperosis y arañas vasculares. SEFAC. 
2012;29‑37.
Parada M, Teixeira S. Maquiagem e camuflagem. RBM; 2008. 
[citad 2016 Jun 10]. p.33‑37. Available from: www.moreirajr.
com.br/revistas.asp?fase=r003&id_materia=3887.
M. M. B. M. M. Gonçalves, M. E. S. R. T. Pina
Braz. J. Pharm. Sci. 2017;53(4):e00182Page 16 / 16
Portugal. Associação Nacional de Farmácias. Rosácea: mais do 
que rubor; 2010. 1 p.
Portugal. Decreto‑Lei n.o 189/2008 de 24 de Setembro ‑ Diário 
da República, 1ª Série. Nº185. 
Portugal. Farmácias Holon - abordagem para a avaliação e 
terapêutica; 2015. 4 p.
Portugal. Farmácias Holon - protocolo de apoio à dispensa de 
MSRM; 2015. 4 p.
Pelle MT, Crawford GH, James WD. Rosacea: II therapy. J Am 
Acad Dermatol. 2004;51(4):499‑512;513‑4. 
Pelle MT. Rosacea. In: Goldsmith, LA; Stephen IK, Gilchrest 
BA, Paller AS, Leffell DJ, Wollf K. Fitzpatrick’s dermatology 
in general medicine. United States of America: McGraw-Hill 
Education/Medical; 2012. p. 918‑919.
Pinheiro LA, Pinheiro AE. A pele da criança. A cosmética 
infantil será um mito? Acta Pediát Port. 2007;38(5):200‑8.
Rodrigo FG, Gomes MM, Silva AM, Lopes P. Dermatologia. 
4th ed. Lisboa: Fundação Calouste Gulbenkian;2010. 1426 p.
Santos ALR. Produtos cosméticos e de higiene corporal 
- enquadramento regulamentar. [citad 2016 May 30]. 
Available from: http://www.ordemfarmaceuticos.pt/xFiles/
scContentDeployer_pt/docs/Docs198.pdf
Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea 
pathophysiology: areview of recent findings. J Am Acad 
Dermatol. 2013;69(6):15‑26.
Two AM, Wiggin W, Gallo RL, Hata TR. Rosacea: Part I. 
Introduction, categorization, histology, pathogenesis, and risk 
factors. J Am Acad Dermatol. 2015;72(5):749‑758.
Two AM, Wu W, Gallo RL, Hata TR. Rosacea: Part II. Topical 
and systemic therapies in the treatment of rosacea. J Am Acad 
Dermatol. 2015;72(5):761‑770.
Weinkle AP, Doktor V, Emer J. Update on the management of 
rosacea. Clin Cosmet Investig Dermatol. 2015;8:159‑177.
Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, et 
al. Standard grading system for rosacea: Report of the National 
Rosacea Society Expert Committee on the Classification and 
Staging of Rosacea. J Am Acad Dermatol. 2004;50(6):907‑912. 
Wolff K, Johnson R, Saavedra A. Dermatologia de Fitzpatrick ‑ 
atlas e texto. 7th ed. Porto Alegre:AMGH;2015. 1152 p.
Received for publication on 16th November 2016
Accepted for publication on 10th April 2017
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
